drugset / Trial / NCT05748145

Metronidazole as Preoperative Therapy in CRC / FusoMetro-001

NCT05748145

Phase 2 Recruiting 40 enrolled Oncology Institute of Southern Switzerland
NaSingle-groupOpen-labelOther

Summary

The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.

Timeline

Start
2023-09-11
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Metronidazole Small molecule 500 mg Oral

Indications